For decades, pharmaceutical companies have competed on search engine results pages. They have optimized keywords, built backlinks, and measured click-through rates. That model has not disappeared — but it is no longer sufficient. A structural shift is underway, and the companies that recognize it early will build durable advantages in digital visibility. Those that do not will find themselves absent from the conversations that matter most.
The shift is called Generative Engine Optimization, or GEO. It describes the discipline of optimising how a brand is represented not in search rankings, but within AI-generated answers — the composite responses that tools like ChatGPT, Gemini, Perplexity, Claude, and Google’s AI Overviews now produce millions of times a day. When a healthcare professional asks an AI system about a treatment pathway, or a patient asks what a diagnosis means, or a policymaker queries the market landscape for a therapy class, the AI does not return ten blue links. It synthesises an answer from sources it deems authoritative, relevant, and reliable. The question for pharmaceutical brands is simple: are you in that answer, and if so, how are you presented?
From Ranking to Referral
The Healthcare Monitor Pharmaceuticals 2026, produced by the Worldcom Public Relations Group, provides one of the first systematic analyses of GEO performance across ten major pharmaceutical companies: AbbVie, AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, and Sanofi. The findings reveal a landscape that is highly uneven — and, crucially, not simply a mirror of traditional brand size or marketing spend.
Pfizer leads on awareness and share of voice — appearing most frequently across the monitored prompt set and occupying the largest proportion of AI response space. Its GEO awareness score of 5.3% reflects both the breadth of its content ecosystem and the depth of its thematic associations across healthcare topics. Novartis, AstraZeneca, and Roche form a strong second tier.
“Early mention can strengthen brand recognition, perceived relevance, and reputation. A company mentioned second or third can exert more influence than a company mentioned later, even if both are present.”
But prominence is not the full picture. AbbVie, despite lower overall awareness, achieves the best average mention position — meaning that when it appears in AI responses, it tends to appear earlier. This is strategically significant. In generative interfaces, the first few examples or companies named carry disproportionate weight, both cognitively and commercially. AbbVie’s performance on this dimension suggests a degree of content precision that pure volume metrics do not capture.
Sentiment, meanwhile, tells its own story. Bristol Myers Squibb achieves the highest sentiment score of the ten companies — 8.6 out of 10 — despite ranking near the bottom on awareness and share of voice. This divergence is instructive. It demonstrates that broad visibility and positive framing are independent variables, and that a company can build a highly favourable AI profile without dominating the volume game.
The NIH Effect — and What It Means for Corporate Domains
Perhaps the most striking finding in the GEO analysis concerns domain citations. When AI systems generate pharmaceutical responses, they draw overwhelmingly from a single source: nih.gov, the National Institutes of Health, which accounts for 51% of all citations — more than thirty times the citation share of any single corporate domain. AbbVie leads among corporate websites at 1.8%, followed by Pfizer at 1.5% and Novartis at 1.3%. The remaining corporate domains receive a fraction of a percentage point each.
This is not a failure of corporate communication. It is a structural reality of how AI systems assign authority in healthcare. Generative models prefer sources that are neutral, evidence-based, and institutionally credible. Corporate domains face an inherent trust gradient compared with government health agencies, peer-reviewed journals, and academic institutions.
The implication is not that pharmaceutical companies should abandon their owned channels — but that they should think beyond them. GEO success in healthcare depends on a distributed authority model: strong proprietary content that is reinforced by an ecosystem of earned references, scientific citations, media coverage, and third-party validation. A company’s AI presence is shaped not only by what it says about itself, but by how the broader information landscape represents it.
What GEO Requires in Practice
Entity clarity: Generative AI systems work with entities — recognizable concepts, organizations, products, and relationships — rather than raw keywords. Pharmaceutical brands must ensure they are clearly and consistently associated with the therapeutic areas, patient populations, and scientific concepts most relevant to their strategic priorities. Ambiguous or inconsistent entity signals reduce citation probability.
Structured, citable content: The content most likely to be used by AI systems is explanatory, evidence-backed, clearly structured, and directly responsive to questions users actually ask. Generic corporate pages perform poorly. Condition overviews, evidence summaries, regulatory Q&As, and expert-authored analyses perform significantly better.
Earned ecosystem investment: Since AI systems weight institutional and third-party authority heavily, pharmaceutical companies must invest in the channels that produce earned citations: peer-reviewed publications, media relations, academic partnerships, conference presence, and scientific communications. These are not new activities — but they must now be understood as GEO infrastructure, not merely PR.
Multilingual and market-specific strategy: AI visibility varies significantly by language, market, and regional context. A brand that performs well in English-language AI responses may be significantly underrepresented in German, French, or Japanese generative environments. For global pharmaceutical companies, GEO must be both globally consistent and locally calibrated.
“GEO is not just about being found. It is about being presented in a way that supports trust, credibility, and leadership.”
The Healthcare Monitor analysis makes clear that GEO maturity is not a binary. It is a multidimensional capability — encompassing awareness, prominence, sentiment, authority, and ecosystem strength. Companies that approach it as a single-metric exercise will optimize for the wrong thing. Those that build across all dimensions will be best positioned to shape how stakeholders encounter and understand their brand in the AI era.
The race for generative visibility in pharmaceuticals has begun. The leaders are already pulling ahead.
